WO2023126969A1 - Oral films of anit-parasitic drugs - Google Patents

Oral films of anit-parasitic drugs Download PDF

Info

Publication number
WO2023126969A1
WO2023126969A1 PCT/IN2022/051136 IN2022051136W WO2023126969A1 WO 2023126969 A1 WO2023126969 A1 WO 2023126969A1 IN 2022051136 W IN2022051136 W IN 2022051136W WO 2023126969 A1 WO2023126969 A1 WO 2023126969A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
film
present
oral
oral film
Prior art date
Application number
PCT/IN2022/051136
Other languages
French (fr)
Inventor
Siva Ramakrishna Velaga
Siva Ramakrishna RAYALA
Srikant PIMPLE
Ajay MACHHA
Original Assignee
Laurus Labs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurus Labs Limited filed Critical Laurus Labs Limited
Publication of WO2023126969A1 publication Critical patent/WO2023126969A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Definitions

  • the present invention relates to new oral dosage form of anti-parasitic drugs and its pharmaceutically acceptable salts thereof, for veterinary use, such as for oral administration to animals. More specifically the present invention relates to oral film compositions comprising anti-parasitic drugs and its pharmaceutically acceptable salts thereof and method of administering the same to the oral cavity of animals for treating parasitic infections.
  • Heartworm which infects in the heart and pulmonary artery, is the major serious and potentially fatal disease in animals, caused by Dirofilaria immitis.
  • Antiparasitic drugs approved by veterinary drug regulatory authorities globally, which is believed to cause interference with invertebrate neurotransmission i.e. it binds to chloride channels in the nerve and muscle cells of parasites, which forces them to stay open, causing paralysis of the affected tissue and killing the parasite.
  • Milbemycin oxime comprised in flavour tablets (2.3mg, 5.75mg, 11.5mg and 23.0mg) were approved in USA (June 1990) under the brand name INTERCEPTOR® to treat heartworm disease caused by Dirofilaria immitis, hookworm infections caused by Ancylostoma caninum, and removal and control of adult roundworm infections caused by Toxocara canis and Toxascaris leonine and whipworm infections caused by Trichuris vulpis in Dogs and puppies and heartworm disease caused by Dirofilaria immitis and the removal of adult Toxocara cati (roundworm) and Ancylostoma tubaeforme (hookworm) infections in Cats and Kittens. Later, an otic Solution comprising a tube contains 0.25 milliliter of a 0.1 percent solution of Milbemycin oxime for treating ear mite infections in cats was approved.
  • Afoxolaner comprised in chewable tablets (11.3 mg, 28.3 mg, 68 mg, or 136 mg were approved in USA(September 2013) under the brand name “NEXGARD®” to treat flea infestations (Ctenocephalides felis), Blacklegged tick (Ixodes scapularis), American Dog tick (Dermacentor variabilis), Lone Star tick (Amblyomma americanum), and Brown Dog tick (Rhipicephalus sanguineus) infestations in dogs.
  • drugs of class macrocyclic lactones Ivermectin, Milbemycin oxime, Moxidectin, Abamectin or Selamectin are effective against Heartworms.
  • Drugs like pyrantel, Febantel, fenbendazole, Emodepside, Piperazine, Mebendazole, and levamisole are effective against Roundworms.
  • Praziquantel is effective against tapeworms.
  • Self-micro emulsifying oral quick-dissolving films for animals which comprises self-microemulsifying component, film-forming material, plasticizer, disintegrant, thickener, and flavouring agent.
  • Self-micro emulsifying components are composed of an oil phase, an emulsifier and a co-emulsifier; the oil phase can be castor oil, olive oil, oleic acid, ethyl oleate, medium chain triglycerides, a mixture of one, two or more of glyceryl oleate and isopropyl myristate; the emulsifier can be selected from polyethylene glycol glycerides, polysorbates, and polyoxyethylene castor oils.
  • the co- emulsifier can be one, two or more mixtures of ethanol, propylene glycol, glycerin, polyethylene glycol, and diethylene glycol monoethyl ether.
  • U.S. patent publication No. 20050136096 discloses edible films for administration of medicaments to animals, wherein the edible film disclosed has an applied coating and a thin film.
  • the applied coating is a powder matrix including one or more medicaments optionally with a carrier is applied as a coating by Sifting, Screening, atomization, Static, mechanical agitation or fluidization etc.
  • the disclosure does not disclose any anti-parasitic drugs or films comprising the same, such edible films are limited by animal’s oral mucosa is being directly exposed to the drugs applied over the film, that may be cause sense of irritability or drooling when administered, resulting in dosing error and reluctance to take such films from next dose onwards.
  • the coated medicament on the thin film may be eroded during the process of administration i.e., while taking out from the package and handling it while administering to the animal.
  • the methods of administering anti-parasitic drugs and its pharmaceutically acceptable salts thereof to animals include vascular injections, muscular injections and oral administration of liquids or flavour tablets or capsules or pills or soft chewables or oral suspensions or oral gels or Pour on solutions or Feed premix or slow release boluses or Drenches or oral powder or Granules or Paste administered through syringe or Injections or drug coating on thin oral films.
  • Disadvantages of these known pharmaceutical delivery methods include difficulty swallowing, difficulty in administration, inconvenience to pet medical staff and pet owners, pain to the animals, cause damage to oral cavity or oesophagus with auxiliary feeders, erosion of drug coating and difficulty in measuring the dosages when liquids or tablets or pills are added to animal feed, since, for example, some time a number of animals or pets will share a common feed container and animals will sometimes try to spit out the medicament, which reduces therapeutic effect in the target animals.
  • Parenteral dosage forms are difficult in administration, also cause pain to the animals, maximum attention while administering and pose a danger of self-administering or injury to the administrating volunteer like pet nursing staff during the process of injecting.
  • the administration is a like an operative procedure, which requires medical attendant and accompanying staff.
  • the present inventors has developed oral film compositions comprising effective amount of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof and method of administering the same in controlling or treating parasitical worm invasions in animals.
  • the major advantages of this novel oral film dosage forms includes reduce difficulty or no difficulty while swallowing, avoid scratches and bites during administration, ease of administration, quick disintegration in the oral cavity besides they are less prone to being spit by the animal.
  • the present invention provides oral film of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof for veterinary use.
  • the present invention provides composition of oral film of Anti- parasitic drugs and its pharmaceutically acceptable salts thereof for veterinary use, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients thereof.
  • the present invention provides process for preparing oral film of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof for veterinary use, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides oral films of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof used for the treatment or prevention of any kind of parasitic infections in animals.
  • references in the specification to “one embodiment,” “an embodiment,” “another embodiment,” “a preferred embodiment,” “one aspect,” “another aspect,” “preferred aspect” and the like, indicate that the embodiment described can include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it is submitted that it is within the knowledge of one of ordinary skill in the art to affect such feature, structure, or characteristic in connection with other embodiments whether or not explicitly described.
  • Films are classified by the site of application. Accordingly, “Oral films” can be formulated to deliver medication to the mouth such as oral hygiene products or to deliver medication to the gastrointestinal tract for absorption. “Buccal films” and “sublingual films” are formulated to facilitate absorption through the proximal mucosal membranes avoiding first pass metabolism or degradation in the gastrointestinal tract and providing a quick onset of action.
  • Oral film according to the present invention may also referred as “Oral thin film,” “OTF,” “ODF,” “oral drug strip” “oral strip”, “veterinary oral film”, “oral disintegrating film” or “oral dissolving film”.
  • veterinary use includes prevention or treatment of veterinary medical conditions in any animal other than human for which oral films of the present invention find useful.
  • Animals herein unless otherwise specified does not limit to only domestic animals such as cats, dogs, guinea pigs, mice, horses, goats, rabbits, swine, apes, primates, hamsters, ferrets, reptiles, sheep, cows, and other non-human animals for which oral films of the present invention find useful.
  • the oral film, according to the present invention preferably disintegrates within about five minutes and more preferably within about 180 seconds upon contact with aqueous media or saliva in oral cavity.
  • an oral film according to the present invention is "non-mucoadhesive" in nature, means that the dosage form is not designed for administration of the active pharmaceutical agent through the oral mucosa i.e. the dosage form is not designed to adhere to the mucosal surfaces of the buccal cavity as an intact film or disintegrated film residue.
  • the invention provides a non-mucoadhesive orally disintegrating film, able to disintegrate upon contact with aqueous media or saliva in oral cavity of the animal within about five minutes and more preferably within about 180 seconds.
  • film includes films, sheets and wafers, in any size and shape, including rectangular, square, or other desired shape. Preferably, they are distinct from pills, tablets, caplets or capsules and wherein the dosage from is like a thin strip of material.
  • the films are generally sufficiently flexible to allow bending or even folding without breaking.
  • the films described herein may be any desired thickness and size such that it may be placed into the oral cavity of the animal.
  • the films may have a thickness of from about 20 microns to about 300 microns. Films may be in a single layer or they may be multilayered, such as laminated or co-extruded films.
  • disintegrating is defined as a state in which any residue of the oral film remaining on the screen of the test apparatus known in the art, or in the mouth of animal, is a soft mass having no palpably film core.
  • the disintegration test does not imply complete solution of dosage unit or even of its active constituent, although a dissolved dosage unit would typically be completely disintegrated.
  • dissolution is defined by the amount of active agent released from the oral film after oral administration or by in-vitro testing known in the art.
  • An in-vitro dissolution test is to evaluate the performance of the product by measuring the amount of active agent dissolved in the dissolution medium.
  • Standardized apparatus known in the art for in-vitro dissolution testing are: USP type I apparatus (basket), USP type II apparatus (Paddle), USP type V apparatus (Paddle over disk).
  • the present invention provides oral film of Anti-parasitic drugs and its pharmaceutically acceptable salt thereof for veterinary use. In another aspect the present invention provides composition and process for preparing oral film of Anti-parasitic drugs and its pharmaceutically acceptable salt thereof for veterinary use.
  • Anti-parasitic drugs according to the present invention are selected from the group comprising of Milbemycin oxime, Ivermectin, Febantel, Albendazole, Thiabendazole, Fenbendazole, Mebendazole, Oxibendazole, Oxfendazole, Cambendazole, Arsenamide sodium, Eprinomectin, Diethylcarbamazine Citrate, Coumaphos, Praziquantel, Levamisole, Levamisole Resinate, Pyrantel, Dichlorophene, Toluene, Trichlorfon, Emodepside, Doramectin, Haloxon, Nitenpyram, N-butyl Chloride, Melarsomine, Piperazine, Piperazinecarbon disulfide complex, Phenothiazine, Dipiperazine, Butamisole, Thenium, Dichlorvos, Bacitracin methylene, Afoxolaner, Selamectin, Moxidectin, Imida
  • Anti-parasitic drugs according to the present invention may also be selected from the combination of two or more drugs like Ivermectin/Praziquantel/Pyrantel, Ivermectin/Pyrantel, Milbemycin Oxime/Praziquantel, Eprinomectin/Praziquantel, Milbemycin Oxime/Afoxolaner, Milbemycin Oxime/Spinosad, Diethylcarbamazine/Oxibendazole, Fenbendazole/Ivermectin/Praziquantel, Lufenuron/Milbemycin Oxime,
  • Oxime/Nitenpyram Lufenuron/Milbemycin Oxime/Praziquantel, Famphur/Levamisole, Levamisole/Piperazine, Moxidectin/Pyrantel/Sarolaner, Piperazin/Thiabendazole, Piperazine/Thiabendazole, Sarolaner/Selamectin, Thiabendazole/Trichlorfon and any combination thereof.
  • Pharmaceutically acceptable salts of Anti-parasitic drugs according to the present invention are selected from sodium, potassium, Magnesium, Fumarate, hydrochloride, Dihydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, Hemisulfate, phosphate, acid phosphate, succinate, acetate, lactate, citrate, tartrate, bitartrate, succinate, maleate, closylate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, Mesylate, Besylate, Salicylate, disalicylate and pamoate.
  • Anti-parasitic drugs and its pharmaceutically acceptable salts thereof according to the present invention are may be present in an amount of about 0.1% to about 75% by weight based on total weight of the composition.
  • the present invention provides composition of oral film of Anti- parasitic drugs and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • one or more pharmaceutically acceptable excipients are selected from the group comprising of suspending/thickening agents, fillers/bulking agents, disintegrating agents, stabilizers, surfactants, sweetening agents, taste masking agents, antifoaming agents, flavoring agents and coloring agents and combinations thereof.
  • the present invention provides oral film of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof comprise one or more film forming polymers.
  • the term “Polymers or Film forming polymers” according to the invention is responsible for imparting adequate mechanical properties to films, and they affect the film disintegration and/or dissolution in oral cavity. Film forming polymers used according to the present invention are not limited to hydrophilic or hydrophobic polymers.
  • Suitable non-limiting hydrophilic film forming polymers according to the present invention are selected from hydroxypropyl methylcellulose or Hypromellose (HPMC), hydroxyethyl cellulose, hydroxypropyl cellulose, sodium carboxy methylcellulose, methyl cellulose, hydroxypropylethylcellulose, povidone, copovidone, polydextrose, polyvinyl alcohol, polyvinyl acetate, polyethylene oxide, pullulan, sodium alginate, propylene glycol alginate, modified starch, gelatin, pectin, polyoxyethylene stearates, poly-epsilon caprolactone, polyglycolized glycerides, cyclodextrins, galactomannans, Polymerized rosin and combinations thereof.
  • HPMC Hypromellose
  • HPMC Hypromellose
  • hydroxyethyl cellulose hydroxypropyl cellulose
  • sodium carboxy methylcellulose sodium carboxy methylcellulose
  • methyl cellulose hydroxypropyle
  • Suitable non-limiting hydrophobic film forming polymers according to the present invention are selected from ethyl cellulose, methyl methacrylate copolymer, Polymethacrylates, polyacrylic acid, copolymers of acrylic acid and alkyl acrylate, carboxyvinyl copolymers and combinations thereof.
  • Polymers used according to present invention are available in various viscosity ranges and are chosen from polymers having viscosity of more than 20 mPa- s.
  • the polymers are chosen with a viscosity of about 20 mPa- s to about 1000 mPa-s. Depending on the viscosity the quantity of the polymer is chosen.
  • Film forming polymer/s according to the present invention may be present in an amount of about 1% to about 60% by weight based on total weight of the composition.
  • the present invention provides oral film of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof comprises plasticizers.
  • plasticizers are responsible for mechanical properties of the film, such as tensile strength and decrease the fragility of film by decreasing the glass transition temperature of polymer.
  • Suitable non-limiting plasticizers according to the present invention are selected from polyethylene glycol, propylene glycol, polyethylene-propylene glycol, glycerol/glycerin, glycerol monoacetate, glycerol diacetate, glycerol triacetate, triacetin, polysorbate, cetyl alcohol, sorbitol, sodium diethylsulfosuccinate, triethyl citrate, tributyl citrate, dimethyl phthalate, diethyl phthalate, dibutyl phthalate and combinations thereof.
  • Plasticizers according to the present invention may be present in an amount of about 1% to about 30% by weight based on total weight of the composition.
  • Suspending/thickening agents according to the present invention are responsible for improving the viscosity of the drug and excipient dispersion preparation and consistency of the oral film.
  • Suitable non-limiting suspending/thickening agents according to the present invention are selected from maltodextrin, natural gums like xanthan gum, carrageen, locust bean gum, cellulose derivatives, dextrin, modified starch and combinations thereof.
  • Suspending/thickening agents according to the present invention may be present in an amount of about 1% to about 50% by weight based on total weight of the composition.
  • Suitable non-limiting filler/bulking agents according to the present invention are selected from Starches, anhydrous lactose, mannitol, Maltodextrin, dicalcium phosphate, calcium sulfate, cellulose, kaolin, sodium chloride, sorbitol, sucrose and combinations thereof.
  • Disintegrating agents according to the present invention are responsible for quick disintegration of oral film upon contact with aqueous media or saliva in oral cavity.
  • Suitable non-limiting Disintegrating agents according to the present invention are selected from Starch, Colloidal silicon dioxide, microcrystalline cellulose, Crospovidone, Sodium Starch glycolate, Croscarmellose sodium and combinations thereof.
  • “Sweetening agent or Sweetener” enhances the palatable/taste and pleasurable factor, which makes the film relatively acceptable or agreeable to the patient.
  • suitable non-limiting sweeteners according to the present invention are selected from glucose (com syrup), dextrose, invert sugar, fructose, and combinations thereof; saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Ammonium Glycyrrhizinate, Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, maltodextrin, xylitol, and the like, hydrogenated starch hydrolysates and the synthetic sweetener 3,6-dihydro-6-methyl-l-l-l,2,3-oxathiazin-4-one-2,2-dioxide,
  • taste masking agents are responsible for blocking or diminishing the bitter taste of drug substance or excipients present in the film.
  • Suitable nonlimiting taste masking agents according to the present invention are selected from ion exchange resins, cyclodextrins and its derivatives, ready made available mixtures of taste mask enhancers and combinations thereof.
  • Suitable non-limiting buffering agents are selected from sodium carbonate, sodium bicarbonate, Citric Acid, Sodium Citrate, potassium carbonate, potassium bicarbonate, Ammonium Phosphate Dibasic, Sodium Phosphate Dibasic, sodium phosphate tribasic, potassium phosphate dibasic, potassium phosphate tribasic, Borate, calcium carbonate, magnesium carbonate, sodium hydroxide, magnesium hydroxide, potassium hydroxide, aluminium hydroxide, and combinations thereof.
  • Stabilizers according to the present invention are responsible for improving the shelf life by preventing the degradation of active agents.
  • Suitable non-limiting stabilizers according to the present invention may be selected Tocopherol, Ascorbic acid, Citric acid, sodium bisulfite, sodium metabisulfite, propyl gallate, Potassium Metabisulfite, butylated hydroxytoluene and butylated hydroxyanisole and combinations thereof.
  • Suitable non-limiting surfactants according to the present invention are selected from cetyl alcohol, sodium lauryl sulfate, Polyoxyl 40 hydrogenated castor oil, Polyoxyl 15 hydroxystearate, Polysorbate 80, Macrogol stearate, Hydrogenated Castor Oil, Spans®, Tweens®, Ethoxylated oils, poloxamers and combinations thereof.
  • Suitable anti-foaming agents according to the present invention are selected from simethicone or dimethicone or any agent that removes air bubbles/entrapped air/void from film-forming compositions.
  • “Flavors” in the present invention are responsible for masking the bitter or nauseating taste of incorporated drug.
  • Suitable non-limiting veterinary acceptable flavoring agents according to the present invention selected from chicken, turkey, beef, pork, lamb, fish, egg, cheese, edible yeast, dairy products which are of either artificially available or naturally available or extracted from meat or organs of animals.
  • Other non-limiting flavoring agents according to the present invention are selected from the group comprising of natural and synthetic flavoring liquids such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof.
  • a non-limiting representative list of examples includes mint oils, cocoa, pea nuts and citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot or other fruit flavors.
  • aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanol (green fruit), and 2-dodecenal (citrus, mandarin), and combinations thereof.
  • aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde
  • Suitable coloring agents according to the present invention are selected from the group comprising of food, drug and cosmetic colors (FD and C), drug and cosmetic colors (D and C), or external drug and cosmetic colors (Ext. D and C). These colors are dyes, their corresponding lakes, and certain natural and derived colorants.
  • Other non-limiting examples of coloring agents according to present invention are selected from known azo dyes, organic or inorganic pigments, or coloring agents of natural origin and combinations thereof.
  • some of the excipients used in the oral film of the present invention may have one or more functions i.e.
  • an excipient used in oral film of the present invention may have multi-function like starch and modified starch used in the present invention may also act as a bulking agent and/or disintegrating agent; Maltodextrin used in the present invention may act as a sweetener and/or suspending/thickening agent and/or filler/bulking agent; Mannitol used in the present invention may act as a sweetener and/or as a filler/bulking agent; cellulose derivatives used in the present invention may act as a film forming polymer and/or suspending/thickening agent.
  • Maltodextrin used in the present invention may act as a sweetener and/or suspending/thickening agent and/or filler/bulking agent
  • Mannitol used in the present invention may act as a sweetener and/or as a filler/bulking agent
  • cellulose derivatives used in the present invention may act as a film forming polymer and/or suspending/thickening agent.
  • the present invention provides composition of oral film of Anti-parasitic drug(s) and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Anti -parasitic drug(s) and its pharmaceutically acceptable salt.
  • the present invention provides composition of oral film of Anti- parasitic drug(s) and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Anti-parasitic drug(s) and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides composition of oral film of Anti- parasitic drug(s) and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Anti-parasitic drug(s) and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer with viscosity of about or more than 20 mPa- s; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides process for preparing oral film of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof for veterinary use, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • Solvents used according to the present invention in the process for preparing oral film of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof may be selected from water, polar organic solvent including, but not limited to ethanol, dichloromethane, isopropanol, acetone, methylene chloride, or any combination thereof.
  • the present invention provides oral film of Milbemycin oxime and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Milbemycin oxime and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Milbemycin oxime and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Milbemycin oxime and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Milbemycin oxime and its pharmaceutically acceptable salt.
  • the present invention provides composition of oral film of Milbemycin oxime and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Milbemycin oxime and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides composition of oral film of Milbemycin oxime and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Milbemycin oxime and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer with viscosity of more than 20 mPa- s; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral film of Afoxolaner and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Afoxolaner and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and optionally one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Afoxolaner and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Afoxolaner and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Afoxolaner and its pharmaceutically acceptable salt.
  • the present invention provides composition of oral film of Afoxolaner and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Afoxolaner and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides composition of oral film of Afoxolaner and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Afoxolaner and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer with viscosity of more than 20 mPa- s; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral film of Praziquantel and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Praziquantel and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Praziquantel and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Praziquantel and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Praziquantel and its pharmaceutically acceptable salt.
  • the present invention provides composition of oral film of Praziquantel and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Praziquantel and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral film of Albendazole and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Albendazole and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Albendazole and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Albendazole and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Albendazole and its pharmaceutically acceptable salt.
  • the present invention provides composition of oral film of Albendazole and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Albendazole and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral film of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts thereof.
  • the present invention provides composition of oral film of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts thereof.
  • the present invention provides composition of oral film of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral film of Milbemycin Oxime/ Afoxolaner combination and its pharmaceutically acceptable salts thereof.
  • the present invention provides composition of oral film of Milbemycin Oxime/Afoxolaner combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salts thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salts thereof.
  • the present invention provides composition of oral film of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salts; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides composition of oral film of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer with viscosity of more than 20 mPa- s; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral film of Eprinomectin and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Eprinomectin and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Eprinomectin and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Eprinomectin and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Eprinomectin and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Eprinomectin and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Eprinomectin and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral film of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof.
  • the present invention provides composition of oral film of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof.
  • the present invention provides composition of oral film of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral film of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof.
  • the present invention provides composition of oral film of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof.
  • the present invention provides composition of oral film of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral film of Ivermectin and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Ivermectin and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Ivermectin and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Ivermectin and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Ivermectin and its pharmaceutically acceptable salt thereof.
  • the present invention provides composition of oral film of Ivermectin and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Ivermectin and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral film of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts thereof.
  • the present invention provides composition of oral film of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for preparing oral film of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
  • the present invention provides composition of oral film of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts thereof.
  • the present invention provides composition of oral film of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
  • the present invention provides oral films of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof used for the treatment or prevention of parasitic infections caused by Heartworms, Lungworms, Nodularworms, kidney worms; Intestinal worms like Tapeworms, Ringworms, Hookworms, Roundworms, whipworms; protozoans (non- worms) like Coccidia, Giardia, spirochetes; and external parasites like Flea, Mites, Ticks and Lice in animals.
  • step 4 Optionally add Polyoxyl 40 hydrogenated castor oil or Polyoxyl 15 hydroxy stearate or Polysorbate 80 or poloxamer to step 3 under stirring and continue stirring till a homogenous dispersion is obtained. 5. Add Milbemycin oxime to the dispersion of step 3/4 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 6 Add Microcrystalline Cellulose to dispersion of step 5 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 7 Add Propylene glycol to dispersion of step 6 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 9 Add colorant to dispersion of step 8 under stirring and continue stirring till a homogenous dispersion is obtained. 10. Add flavor to dispersion of step 9 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 11 Homogenize the dispersion of step 10 using a homogenizer to obtain a homogenous dispersion. 12. If any foam observed, de-aerate the dispersion by applying vacuum under slow stirring.
  • step 11/12 The dispersion of step 11/12 is casted using a film casting machine where the dispersion is spreaded on a backing film to form a thin wet film which passed through a drying zone.
  • the dried film is cut into a desired size by using slitter.
  • step 3 Add Hydroxypropyl cellulose and/or polyvinyl alcohol to step 2 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 4 Optionally add Polyoxyl 40 hydrogenated castor oil or Polyoxyl 15 hydroxy stearate or Polysorbate 80 or poloxamer to step 3 under stirring and continue stirring till a homogenous dispersion is obtained. 5. Add Afoxolaner to the dispersion of step 3/4 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 6 Add Starch to dispersion of step 5 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 7 Add Propylene glycol to dispersion of step 6 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 8 Add colorant to dispersion of step 8 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 10 Add, flavor to dispersion of step 9 under stirring and continue stirring till a homogenous dispersion is obtained.
  • step 10 Homogenize the suspension of step 10 using a homogenizer to obtain a homogenous dispersion.
  • step 11/12 The dispersion of step 11/12 is casted using a film casting machine where the dispersion is spreaded on a backing film to form a thin wet film which passed through a drying zone.
  • the dried film is cut into a desired size by using slitter.
  • step 2 Added Propylene glycol to dispersion of step 1 under stirring and continued stirring till a homogenous dispersion is obtained.
  • step 4 Added Crospovidone to step 3 under stirring and continued stirring till a homogenous dispersion is obtained.
  • step 5 Added flavor to dispersion of step 4 under stirring and continued stirring till a homogenous dispersion is obtained.
  • step 7 Added Milbemycin oxime to the solution of step 6 and stirred with a suitable stirrer to get a homogenous dispersion.
  • step 7 was added to the polymeric suspension of step 5 and homogenized using a homogenizer to obtain a homogenous suspension.
  • the dispersion is casted using a film casting machine where the dispersion is spreaded on a backing film to form a thin wet film which passed through a drying zone.
  • the dried film is cut into a desired size by using slitter.
  • Disintegration study The obtained oral film of Example 3 is tested for disintegration time using static method, wherein the oral film is placed in a petri dish containing water in a static condition and the time taken for disintegration is observed.
  • oral films of the present invention formulated according to an embodiment has shown quick disintegration, which solves the problems mentioned above like difficulty of administration, swallowing, dosing errors etc in animals.

Abstract

The present invention relates to new oral dosage forms of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof for veterinary use, such as for oral administration to animals. More specifically the present invention provides compositions and process for preparing oral film comprising Anti-parasitic drugs and its pharmaceutically acceptable salts thereof.

Description

ORAL FILMS OF ANIT-PARASITIC DRUGS
FIELD OF THE INVENTION
The present invention relates to new oral dosage form of anti-parasitic drugs and its pharmaceutically acceptable salts thereof, for veterinary use, such as for oral administration to animals. More specifically the present invention relates to oral film compositions comprising anti-parasitic drugs and its pharmaceutically acceptable salts thereof and method of administering the same to the oral cavity of animals for treating parasitic infections.
BACKGROUND OF THE INVENTION
Due to a rapid growth in per capita income globally and improvement of people's living standards, the culture of maintaining domestic animals or pets as house hold has raised. The pet population has grown drastically over the period of year. Dogs are the most popular pets in households, while cats have become the second-preferred option, followed by fish and birds. Other pets, such as dogs used for police work and search and rescue operations, race horses, etc., each play a significant role in society. On another side, Animal husbandry and Dairying is a critical industry for ecological and environmental survival. Animal husbandry requires continuous nurturing of animals for meat, fibre, milk or for aiding agricultural purposes. As the Animal husbandry, Dairying and pet culture diversified over years, effective veterinary care is also growing on par with culture. Currently, veterinary care has become very important to the animal owners as well as the rest of society. The proper and efficient veterinary care of these pets and other animals is very important for overall ecosystem development.
Accordingly, demand for high quality and ease of administering the veterinary medicines has also seen a growth, as these animals are been prone to many illness and injuries. The most regular clinical illnesses suffered by animals are parasitic infections, caused by internal parasites also known as Endoparasites like worms such as Heartworms, lungworms, nodular worms, kidney worms and intestinal worms like Tapeworms, Ringworms, Hookworms, Roundworms, whipworms; protozoans (non-worms) like Coccidia, Giardia, spirochetes and external parasites also known as Ectoparasites like Flea, Mites, Ticks and Lice.
Heartworm, which infects in the heart and pulmonary artery, is the major serious and potentially fatal disease in animals, caused by Dirofilaria immitis. To treat or control of such parasitic infections in animals, there are several effective Antiparasitic drugs approved by veterinary drug regulatory authorities globally, which is believed to cause interference with invertebrate neurotransmission i.e. it binds to chloride channels in the nerve and muscle cells of parasites, which forces them to stay open, causing paralysis of the affected tissue and killing the parasite.
Following are the known widely used approved Anti-parasitic drugs:
Milbemycin oxime comprised in flavour tablets (2.3mg, 5.75mg, 11.5mg and 23.0mg) were approved in USA (June 1990) under the brand name INTERCEPTOR® to treat heartworm disease caused by Dirofilaria immitis, hookworm infections caused by Ancylostoma caninum, and removal and control of adult roundworm infections caused by Toxocara canis and Toxascaris leonine and whipworm infections caused by Trichuris vulpis in Dogs and puppies and heartworm disease caused by Dirofilaria immitis and the removal of adult Toxocara cati (roundworm) and Ancylostoma tubaeforme (hookworm) infections in Cats and Kittens. Later, an otic Solution comprising a tube contains 0.25 milliliter of a 0.1 percent solution of Milbemycin oxime for treating ear mite infections in cats was approved.
Afoxolaner comprised in chewable tablets (11.3 mg, 28.3 mg, 68 mg, or 136 mg were approved in USA(September 2013) under the brand name “NEXGARD®” to treat flea infestations (Ctenocephalides felis), Blacklegged tick (Ixodes scapularis), American Dog tick (Dermacentor variabilis), Lone Star tick (Amblyomma americanum), and Brown Dog tick (Rhipicephalus sanguineus) infestations in dogs.
Further known drugs like Ivermectin, Febantel, Albendazole, Thiabendazole, Fenbendazole, Mebendazole, Oxibendazole, Oxfendazole, Cambendazole, Arsenamide sodium, Eprinomectin, Diethylcarbamazine Citrate, Coumaphos, Abamectin, Praziquantel, Levamisole hydrochloride, Levamisole Resinate, Pyrantel pamoate, Pyrantel Tartrate, Dichlorophene, Toluene, Trichlorfon, Emodepside, Doramectin, Haloxon, Nitenpyram, N- butyl Chloride, Melarsomine dihydrochloride, Piperazine Monohydrochloride, Piperazinecarbon disulfide complex, Phenothiazine, Dipiperazine Sulfate, Butamisole hydrochloride, Thenium closylate, Dichlorvos, Bacitracin methylene disalicylate, Selamectin, Moxidectin, Imidacloprid, Spinosad, Lufenuron, Cythioate, Fenthion, Sarolaner, Fluralaner, Famphur, Phosmet, Lotilaner, Griseofulvin, Morantel tartrate, Bunamidine hydrochloride, Tolnaftate, Tioxidazole etc., and any combinations thereof are approved by USFDA for treating parasitic infections in animals. All these drugs are available in various dosage forms like flavor tablets, Capsules, Chewable tablets, oral suspensions, oral gels, Pour on solutions, Premix, Drench, oral powder, Granules, Paste administered through syringe, Topical solutions, Spray, Slow release boluses, Top dressing on feed and Injections.
It is also known that drugs of class macrocyclic lactones, Ivermectin, Milbemycin oxime, Moxidectin, Abamectin or Selamectin are effective against Heartworms. Drugs like pyrantel, Febantel, fenbendazole, Emodepside, Piperazine, Mebendazole, and levamisole are effective against Roundworms. Praziquantel is effective against tapeworms.
Further known combinations of two or more anti-parasitic drugs like Ivermectin/Praziquantel/Pyrantel, Ivermectin/Pyrantel, Milbemycin Oxime/Praziquantel, Eprinomectin/Praziquantel, Milbemycin oxime/Afoxolaner, Milbemycin Oxime/Spinosad, Afoxolaner/Eprinomectin/Praziquantel, Diethylcarbamazine Citrate/Oxibendazole, Fenbendazole/Ivermectin/Praziquantel, Lufenuron/Milbemycin Oxime,
Dichlorophene/Toluene, Piperazine Phosphate/Thenium Closylate, Praziquantel/Pyrantel Pamoate, Febantel/Praziquantel/Pyrantel, Emodepside/Praziquantel, Febantel/Praziquantel, Mebendazole/Trichlorfon, Oxfendazole/Trichlorfon, Phenothiazine/Piperazine Dihydrochloride/Trichlorfon, Phenothiazine/Piperazine-carbon Disulfide Complex, Bacitracin methylene disalicylate/Fenbendazole, Bacitracin methylene disalicylate/Ivermectin, Dipiperazine Sulfate/Piperazine, Ivermectin/Praziquantel, Imidacloprid/Ivermectin, Imidacloprid/Moxidectin, Lufenuron/Milbemycin,
Oxime/Nitenpyram, Lufenuron/Milbemycin Oxime/Praziquantel, Famphur/Levamisole Resinate, Levamisole Hydrochloride/Piperazine Dihydrochloride, Moxidectin/Pyrantel Pamoate/Sarolaner, Piperazine Citrate/Thiabendazole, Piperazine Phosphate/Thiabendazole, Sarolaner/Selamectin, Thiabendazole/Trichlorfon etc., were approved by USFDA for Veterinary medicine to use in animals by concomitant, concurrent, sequential or programmed administration to control and treat multiple parasitic infections and these combination products are available in various dosage forms like flavor tablets, Capsules, Chewable tablets, oral suspensions, oral gels, Pour on solutions, Premix, slow release boluses, Drenches, oral powder, Granules, Paste administered through syringe, Topical solutions, Spray, Top dressing on feed, Injections and any combination dosage forms thereof.
CN109172547A patent publication discloses self-micro emulsifying oral quick-dissolving films for animals, which comprises self-microemulsifying component, film-forming material, plasticizer, disintegrant, thickener, and flavouring agent. Self-micro emulsifying components are composed of an oil phase, an emulsifier and a co-emulsifier; the oil phase can be castor oil, olive oil, oleic acid, ethyl oleate, medium chain triglycerides, a mixture of one, two or more of glyceryl oleate and isopropyl myristate; the emulsifier can be selected from polyethylene glycol glycerides, polysorbates, and polyoxyethylene castor oils. The co- emulsifier can be one, two or more mixtures of ethanol, propylene glycol, glycerin, polyethylene glycol, and diethylene glycol monoethyl ether.
U.S. patent publication No. 20050136096 discloses edible films for administration of medicaments to animals, wherein the edible film disclosed has an applied coating and a thin film. The applied coating is a powder matrix including one or more medicaments optionally with a carrier is applied as a coating by Sifting, Screening, atomization, Static, mechanical agitation or fluidization etc. Though the disclosure does not disclose any anti-parasitic drugs or films comprising the same, such edible films are limited by animal’s oral mucosa is being directly exposed to the drugs applied over the film, that may be cause sense of irritability or drooling when administered, resulting in dosing error and reluctance to take such films from next dose onwards. Also, the coated medicament on the thin film may be eroded during the process of administration i.e., while taking out from the package and handling it while administering to the animal.
It is well known from the arts that the methods of administering anti-parasitic drugs and its pharmaceutically acceptable salts thereof to animals include vascular injections, muscular injections and oral administration of liquids or flavour tablets or capsules or pills or soft chewables or oral suspensions or oral gels or Pour on solutions or Feed premix or slow release boluses or Drenches or oral powder or Granules or Paste administered through syringe or Injections or drug coating on thin oral films. Disadvantages of these known pharmaceutical delivery methods include difficulty swallowing, difficulty in administration, inconvenience to pet medical staff and pet owners, pain to the animals, cause damage to oral cavity or oesophagus with auxiliary feeders, erosion of drug coating and difficulty in measuring the dosages when liquids or tablets or pills are added to animal feed, since, for example, some time a number of animals or pets will share a common feed container and animals will sometimes try to spit out the medicament, which reduces therapeutic effect in the target animals. Parenteral dosage forms are difficult in administration, also cause pain to the animals, maximum attention while administering and pose a danger of self-administering or injury to the administrating volunteer like pet nursing staff during the process of injecting. Moreover, the administration is a like an operative procedure, which requires medical attendant and accompanying staff. Thus, there is need for an effective, pliable, easily administrable dosage form for the pet owner or any volunteer with required minimal attention.
Solving the problems of pets or animal’s reluctance to swallow and poor compliance to known dosage forms has become the focus of the development of new or alternate dosage forms for oral administration of animals. Accordingly, it is also the main aim of the present inventors to provide a veterinary delivery system for effective absorption into the animal’s vascular system through gastro intestinal tract, have dose delivery accuracy, easy way to administer and shows maximum therapeutic effect.
Keeping this in mind, the present inventors has developed oral film compositions comprising effective amount of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof and method of administering the same in controlling or treating parasitical worm invasions in animals. The major advantages of this novel oral film dosage forms includes reduce difficulty or no difficulty while swallowing, avoid scratches and bites during administration, ease of administration, quick disintegration in the oral cavity besides they are less prone to being spit by the animal.
SUMMARY OF THE INVENTION
In one embodiment, the present invention provides oral film of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof for veterinary use.
In a preferred embodiment, the present invention provides composition of oral film of Anti- parasitic drugs and its pharmaceutically acceptable salts thereof for veterinary use, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients thereof.
In another embodiment, the present invention provides process for preparing oral film of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof for veterinary use, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology. In another embodiment, the present invention provides oral films of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof used for the treatment or prevention of any kind of parasitic infections in animals.
DETAILED DESCRIPTION OF THE INVENTION
References in the specification to “one embodiment,” “an embodiment,” “another embodiment,” “a preferred embodiment,” “one aspect,” “another aspect,” “preferred aspect” and the like, indicate that the embodiment described can include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it is submitted that it is within the knowledge of one of ordinary skill in the art to affect such feature, structure, or characteristic in connection with other embodiments whether or not explicitly described.
As per United States Pharmacopoeia, Films are classified by the site of application. Accordingly, “Oral films” can be formulated to deliver medication to the mouth such as oral hygiene products or to deliver medication to the gastrointestinal tract for absorption. “Buccal films” and “sublingual films” are formulated to facilitate absorption through the proximal mucosal membranes avoiding first pass metabolism or degradation in the gastrointestinal tract and providing a quick onset of action.
“Oral film” according to the present invention may also referred as “Oral thin film,” “OTF,” “ODF,” “oral drug strip” “oral strip”, “veterinary oral film”, “oral disintegrating film” or “oral dissolving film”.
The term “veterinary use” according to the present invention includes prevention or treatment of veterinary medical conditions in any animal other than human for which oral films of the present invention find useful. Animals herein unless otherwise specified does not limit to only domestic animals such as cats, dogs, guinea pigs, mice, horses, goats, rabbits, swine, apes, primates, hamsters, ferrets, reptiles, sheep, cows, and other non-human animals for which oral films of the present invention find useful. The oral film, according to the present invention preferably disintegrates within about five minutes and more preferably within about 180 seconds upon contact with aqueous media or saliva in oral cavity.
An oral film according to the present invention is "non-mucoadhesive" in nature, means that the dosage form is not designed for administration of the active pharmaceutical agent through the oral mucosa i.e. the dosage form is not designed to adhere to the mucosal surfaces of the buccal cavity as an intact film or disintegrated film residue. In particular, the invention provides a non-mucoadhesive orally disintegrating film, able to disintegrate upon contact with aqueous media or saliva in oral cavity of the animal within about five minutes and more preferably within about 180 seconds.
The term “film” according to the present invention includes films, sheets and wafers, in any size and shape, including rectangular, square, or other desired shape. Preferably, they are distinct from pills, tablets, caplets or capsules and wherein the dosage from is like a thin strip of material. The films are generally sufficiently flexible to allow bending or even folding without breaking. The films described herein may be any desired thickness and size such that it may be placed into the oral cavity of the animal. The films may have a thickness of from about 20 microns to about 300 microns. Films may be in a single layer or they may be multilayered, such as laminated or co-extruded films.
The term “disintegrating” according to present invention is defined as a state in which any residue of the oral film remaining on the screen of the test apparatus known in the art, or in the mouth of animal, is a soft mass having no palpably film core. The disintegration test does not imply complete solution of dosage unit or even of its active constituent, although a dissolved dosage unit would typically be completely disintegrated.
The term “dissolution” according to present invention is defined by the amount of active agent released from the oral film after oral administration or by in-vitro testing known in the art. An in-vitro dissolution test is to evaluate the performance of the product by measuring the amount of active agent dissolved in the dissolution medium. Standardized apparatus known in the art for in-vitro dissolution testing are: USP type I apparatus (basket), USP type II apparatus (Paddle), USP type V apparatus (Paddle over disk).
In one aspect the present invention provides oral film of Anti-parasitic drugs and its pharmaceutically acceptable salt thereof for veterinary use. In another aspect the present invention provides composition and process for preparing oral film of Anti-parasitic drugs and its pharmaceutically acceptable salt thereof for veterinary use.
Anti-parasitic drugs according to the present invention are selected from the group comprising of Milbemycin oxime, Ivermectin, Febantel, Albendazole, Thiabendazole, Fenbendazole, Mebendazole, Oxibendazole, Oxfendazole, Cambendazole, Arsenamide sodium, Eprinomectin, Diethylcarbamazine Citrate, Coumaphos, Praziquantel, Levamisole, Levamisole Resinate, Pyrantel, Dichlorophene, Toluene, Trichlorfon, Emodepside, Doramectin, Haloxon, Nitenpyram, N-butyl Chloride, Melarsomine, Piperazine, Piperazinecarbon disulfide complex, Phenothiazine, Dipiperazine, Butamisole, Thenium, Dichlorvos, Bacitracin methylene, Afoxolaner, Selamectin, Moxidectin, Imidacloprid, Spinosad, Lufenuron, Cythioate, Fenthion, Sarolaner, Fluralaner, Famphur, Phosmet, Lotilaner, Griseofulvin, Morantel, Bunamidine, Tolnaftate, Tioxidazole etc. and its pharmaceutically acceptable salts thereof.
Anti-parasitic drugs according to the present invention may also be selected from the combination of two or more drugs like Ivermectin/Praziquantel/Pyrantel, Ivermectin/Pyrantel, Milbemycin Oxime/Praziquantel, Eprinomectin/Praziquantel, Milbemycin Oxime/Afoxolaner, Milbemycin Oxime/Spinosad, Diethylcarbamazine/Oxibendazole, Fenbendazole/Ivermectin/Praziquantel, Lufenuron/Milbemycin Oxime,
Dichlorophene/Toluene, Piperazine/Thenium, Praziquantcl/Pyrantcl,
Febantel/Praziquantel/Pyrantel, Emodepside/Praziquantel, Fcbantcl/Praziquantcl, Mebendazole/Trichlorfon, Oxfendazole/Trichlorfon, Pheno thiazine/Piperazine/Trichlorfon, Phenothiazine/Piperazine-carbon Disulfide Complex, Bacitracin methylene/Fenbendazole, Bacitracin methylene/Ivermectin, Dipiperazine/Piperazine, Ivermectin/Praziquantel, Imidacloprid/Ivermectin, Imidacloprid/Moxidectin, Lufenuron/Milbemycin,
Oxime/Nitenpyram, Lufenuron/Milbemycin Oxime/Praziquantel, Famphur/Levamisole, Levamisole/Piperazine, Moxidectin/Pyrantel/Sarolaner, Piperazin/Thiabendazole, Piperazine/Thiabendazole, Sarolaner/Selamectin, Thiabendazole/Trichlorfon and any combination thereof.
Pharmaceutically acceptable salts of Anti-parasitic drugs according to the present invention are selected from sodium, potassium, Magnesium, Fumarate, hydrochloride, Dihydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, Hemisulfate, phosphate, acid phosphate, succinate, acetate, lactate, citrate, tartrate, bitartrate, succinate, maleate, closylate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p- toluenesulfonate, Mesylate, Besylate, Salicylate, disalicylate and pamoate.
Anti-parasitic drugs and its pharmaceutically acceptable salts thereof according to the present invention are may be present in an amount of about 0.1% to about 75% by weight based on total weight of the composition.
In one preferred aspect, the present invention provides composition of oral film of Anti- parasitic drugs and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
According to the present invention, one or more pharmaceutically acceptable excipients are selected from the group comprising of suspending/thickening agents, fillers/bulking agents, disintegrating agents, stabilizers, surfactants, sweetening agents, taste masking agents, antifoaming agents, flavoring agents and coloring agents and combinations thereof.
In another aspect, the present invention provides oral film of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof comprise one or more film forming polymers. The term “Polymers or Film forming polymers” according to the invention is responsible for imparting adequate mechanical properties to films, and they affect the film disintegration and/or dissolution in oral cavity. Film forming polymers used according to the present invention are not limited to hydrophilic or hydrophobic polymers.
Suitable non-limiting hydrophilic film forming polymers according to the present invention are selected from hydroxypropyl methylcellulose or Hypromellose (HPMC), hydroxyethyl cellulose, hydroxypropyl cellulose, sodium carboxy methylcellulose, methyl cellulose, hydroxypropylethylcellulose, povidone, copovidone, polydextrose, polyvinyl alcohol, polyvinyl acetate, polyethylene oxide, pullulan, sodium alginate, propylene glycol alginate, modified starch, gelatin, pectin, polyoxyethylene stearates, poly-epsilon caprolactone, polyglycolized glycerides, cyclodextrins, galactomannans, Polymerized rosin and combinations thereof.
Suitable non-limiting hydrophobic film forming polymers according to the present invention are selected from ethyl cellulose, methyl methacrylate copolymer, Polymethacrylates, polyacrylic acid, copolymers of acrylic acid and alkyl acrylate, carboxyvinyl copolymers and combinations thereof.
Polymers used according to present invention are available in various viscosity ranges and are chosen from polymers having viscosity of more than 20 mPa- s. Preferably, the polymers are chosen with a viscosity of about 20 mPa- s to about 1000 mPa-s. Depending on the viscosity the quantity of the polymer is chosen.
Film forming polymer/s according to the present invention may be present in an amount of about 1% to about 60% by weight based on total weight of the composition.
In an aspect, the present invention provides oral film of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof comprises plasticizers. The term “plasticizers” according to the present invention are responsible for mechanical properties of the film, such as tensile strength and decrease the fragility of film by decreasing the glass transition temperature of polymer. Suitable non-limiting plasticizers according to the present invention are selected from polyethylene glycol, propylene glycol, polyethylene-propylene glycol, glycerol/glycerin, glycerol monoacetate, glycerol diacetate, glycerol triacetate, triacetin, polysorbate, cetyl alcohol, sorbitol, sodium diethylsulfosuccinate, triethyl citrate, tributyl citrate, dimethyl phthalate, diethyl phthalate, dibutyl phthalate and combinations thereof.
Plasticizers according to the present invention may be present in an amount of about 1% to about 30% by weight based on total weight of the composition.
Suspending/thickening agents according to the present invention are responsible for improving the viscosity of the drug and excipient dispersion preparation and consistency of the oral film. Suitable non-limiting suspending/thickening agents according to the present invention are selected from maltodextrin, natural gums like xanthan gum, carrageen, locust bean gum, cellulose derivatives, dextrin, modified starch and combinations thereof.
Suspending/thickening agents according to the present invention may be present in an amount of about 1% to about 50% by weight based on total weight of the composition.
Suitable non-limiting filler/bulking agents according to the present invention are selected from Starches, anhydrous lactose, mannitol, Maltodextrin, dicalcium phosphate, calcium sulfate, cellulose, kaolin, sodium chloride, sorbitol, sucrose and combinations thereof. Disintegrating agents according to the present invention are responsible for quick disintegration of oral film upon contact with aqueous media or saliva in oral cavity. Suitable non-limiting Disintegrating agents according to the present invention are selected from Starch, Colloidal silicon dioxide, microcrystalline cellulose, Crospovidone, Sodium Starch glycolate, Croscarmellose sodium and combinations thereof.
“Sweetening agent or Sweetener” according to the present invention enhances the palatable/taste and pleasurable factor, which makes the film relatively acceptable or agreeable to the patient. Suitable non-limiting sweeteners according to the present invention are selected from glucose (com syrup), dextrose, invert sugar, fructose, and combinations thereof; saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Ammonium Glycyrrhizinate, Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, maltodextrin, xylitol, and the like, hydrogenated starch hydrolysates and the synthetic sweetener 3,6-dihydro-6-methyl-l-l-l,2,3-oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (Acesulfame-K), and sodium and calcium salts thereof, natural intensive sweeteners, protein based sweeteners such as thaumatoccous danielli (Thaumatin I and II) and combinations thereof.
“Taste masking agents” according to the present invention are responsible for blocking or diminishing the bitter taste of drug substance or excipients present in the film. Suitable nonlimiting taste masking agents according to the present invention are selected from ion exchange resins, cyclodextrins and its derivatives, ready made available mixtures of taste mask enhancers and combinations thereof.
Suitable non-limiting buffering agents according to the present invention are selected from sodium carbonate, sodium bicarbonate, Citric Acid, Sodium Citrate, potassium carbonate, potassium bicarbonate, Ammonium Phosphate Dibasic, Sodium Phosphate Dibasic, sodium phosphate tribasic, potassium phosphate dibasic, potassium phosphate tribasic, Borate, calcium carbonate, magnesium carbonate, sodium hydroxide, magnesium hydroxide, potassium hydroxide, aluminium hydroxide, and combinations thereof.
Stabilizers according to the present invention are responsible for improving the shelf life by preventing the degradation of active agents. Suitable non-limiting stabilizers according to the present invention may be selected Tocopherol, Ascorbic acid, Citric acid, sodium bisulfite, sodium metabisulfite, propyl gallate, Potassium Metabisulfite, butylated hydroxytoluene and butylated hydroxyanisole and combinations thereof.
Suitable non-limiting surfactants according to the present invention are selected from cetyl alcohol, sodium lauryl sulfate, Polyoxyl 40 hydrogenated castor oil, Polyoxyl 15 hydroxystearate, Polysorbate 80, Macrogol stearate, Hydrogenated Castor Oil, Spans®, Tweens®, Ethoxylated oils, poloxamers and combinations thereof.
Suitable anti-foaming agents according to the present invention are selected from simethicone or dimethicone or any agent that removes air bubbles/entrapped air/void from film-forming compositions.
“Flavors” in the present invention are responsible for masking the bitter or nauseating taste of incorporated drug. Suitable non-limiting veterinary acceptable flavoring agents according to the present invention selected from chicken, turkey, beef, pork, lamb, fish, egg, cheese, edible yeast, dairy products which are of either artificially available or naturally available or extracted from meat or organs of animals. Other non-limiting flavoring agents according to the present invention are selected from the group comprising of natural and synthetic flavoring liquids such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof. A non-limiting representative list of examples includes mint oils, cocoa, pea nuts and citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot or other fruit flavors. Other useful flavorings include aldehydes and esters such as benzaldehyde (cherry, almond), citral i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanol (green fruit), and 2-dodecenal (citrus, mandarin), and combinations thereof.
Suitable coloring agents according to the present invention are selected from the group comprising of food, drug and cosmetic colors (FD and C), drug and cosmetic colors (D and C), or external drug and cosmetic colors (Ext. D and C). These colors are dyes, their corresponding lakes, and certain natural and derived colorants. Other non-limiting examples of coloring agents according to present invention are selected from known azo dyes, organic or inorganic pigments, or coloring agents of natural origin and combinations thereof. According to an aspect, some of the excipients used in the oral film of the present invention may have one or more functions i.e. an excipient used in oral film of the present invention may have multi-function like starch and modified starch used in the present invention may also act as a bulking agent and/or disintegrating agent; Maltodextrin used in the present invention may act as a sweetener and/or suspending/thickening agent and/or filler/bulking agent; Mannitol used in the present invention may act as a sweetener and/or as a filler/bulking agent; cellulose derivatives used in the present invention may act as a film forming polymer and/or suspending/thickening agent. Hence, a skilled person should not construe the limit of an excipient stated or illustrated in any aspect or embodiment or an example of oral film in the present invention to a single function.
In a preferred aspect, the present invention provides composition of oral film of Anti-parasitic drug(s) and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Anti -parasitic drug(s) and its pharmaceutically acceptable salt.
In another preferred aspect, the present invention provides composition of oral film of Anti- parasitic drug(s) and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Anti-parasitic drug(s) and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In a further preferred aspect, the present invention provides composition of oral film of Anti- parasitic drug(s) and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Anti-parasitic drug(s) and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer with viscosity of about or more than 20 mPa- s; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In one aspect, the present invention provides process for preparing oral film of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof for veterinary use, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
Solvents used according to the present invention in the process for preparing oral film of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof may be selected from water, polar organic solvent including, but not limited to ethanol, dichloromethane, isopropanol, acetone, methylene chloride, or any combination thereof.
In one preferred aspect, the present invention provides oral film of Milbemycin oxime and its pharmaceutically acceptable salt thereof.
In one preferred aspect, the present invention provides composition of oral film of Milbemycin oxime and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
In one aspect, the present invention provides process for preparing oral film of Milbemycin oxime and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
In a preferred aspect, the present invention provides composition of oral film of Milbemycin oxime and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Milbemycin oxime and its pharmaceutically acceptable salt.
In another preferred aspect, the present invention provides composition of oral film of Milbemycin oxime and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Milbemycin oxime and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In a further preferred aspect, the present invention provides composition of oral film of Milbemycin oxime and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Milbemycin oxime and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer with viscosity of more than 20 mPa- s; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In one preferred aspect, the present invention provides oral film of Afoxolaner and its pharmaceutically acceptable salt thereof.
In one preferred aspect, the present invention provides composition of oral film of Afoxolaner and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and optionally one or more pharmaceutically acceptable excipients.
In one aspect, the present invention provides process for preparing oral film of Afoxolaner and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
In a preferred aspect, the present invention provides composition of oral film of Afoxolaner and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Afoxolaner and its pharmaceutically acceptable salt.
In another preferred aspect, the present invention provides composition of oral film of Afoxolaner and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Afoxolaner and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In a further preferred aspect, the present invention provides composition of oral film of Afoxolaner and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Afoxolaner and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer with viscosity of more than 20 mPa- s; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In one preferred aspect, the present invention provides oral film of Praziquantel and its pharmaceutically acceptable salt thereof.
In one preferred aspect, the present invention provides composition of oral film of Praziquantel and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
In one aspect, the present invention provides process for preparing oral film of Praziquantel and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
In a preferred aspect, the present invention provides composition of oral film of Praziquantel and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Praziquantel and its pharmaceutically acceptable salt.
In another preferred aspect, the present invention provides composition of oral film of Praziquantel and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Praziquantel and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In one preferred aspect, the present invention provides oral film of Albendazole and its pharmaceutically acceptable salt thereof.
In one preferred aspect, the present invention provides composition of oral film of Albendazole and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
In one aspect, the present invention provides process for preparing oral film of Albendazole and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
In a preferred aspect, the present invention provides composition of oral film of Albendazole and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Albendazole and its pharmaceutically acceptable salt.
In another preferred aspect, the present invention provides composition of oral film of Albendazole and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Albendazole and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In one preferred aspect, the present invention provides oral film of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts thereof.
In one preferred aspect, the present invention provides composition of oral film of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
In one aspect, the present invention provides process for preparing oral film of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
In a preferred aspect, the present invention provides composition of oral film of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts thereof.
In another preferred aspect, the present invention provides composition of oral film of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Milbemycin oxime/Praziquantel combination and its pharmaceutically acceptable salts; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In one preferred aspect, the present invention provides oral film of Milbemycin Oxime/ Afoxolaner combination and its pharmaceutically acceptable salts thereof.
In one preferred aspect, the present invention provides composition of oral film of Milbemycin Oxime/Afoxolaner combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
In one aspect, the present invention provides process for preparing oral film of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salts thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
In a preferred aspect, the present invention provides composition of oral film of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salts thereof.
In another preferred aspect, the present invention provides composition of oral film of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salts; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In a further preferred aspect, the present invention provides composition of oral film of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salt thereof for veterinary use, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Milbemycin oxime/ Afoxolaner combination and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer with viscosity of more than 20 mPa- s; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In one preferred aspect, the present invention provides oral film of Eprinomectin and its pharmaceutically acceptable salt thereof.
In one preferred aspect, the present invention provides composition of oral film of Eprinomectin and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
In one aspect, the present invention provides process for preparing oral film of Eprinomectin and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology. In a preferred aspect, the present invention provides composition of oral film of Eprinomectin and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Eprinomectin and its pharmaceutically acceptable salt thereof.
In another preferred aspect, the present invention provides composition of oral film of Eprinomectin and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Eprinomectin and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In one preferred aspect, the present invention provides oral film of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof.
In one preferred aspect, the present invention provides composition of oral film of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
In one aspect, the present invention provides process for preparing oral film of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
In a preferred aspect, the present invention provides composition of oral film of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof.
In another preferred aspect, the present invention provides composition of oral film of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In one preferred aspect, the present invention provides oral film of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof.
In one preferred aspect, the present invention provides composition of oral film of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
In one aspect, the present invention provides process for preparing oral film of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
In a preferred aspect, the present invention provides composition of oral film of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof.
In another preferred aspect, the present invention provides composition of oral film of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Afoxolaner/Eprinomectin/Praziquantel combination and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In one preferred aspect, the present invention provides oral film of Ivermectin and its pharmaceutically acceptable salt thereof.
In one preferred aspect, the present invention provides composition of oral film of Ivermectin and its pharmaceutically acceptable salt thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients.
In one aspect, the present invention provides process for preparing oral film of Ivermectin and its pharmaceutically acceptable salt thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
In a preferred aspect, the present invention provides composition of oral film of Ivermectin and its pharmaceutically acceptable salt thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Ivermectin and its pharmaceutically acceptable salt thereof.
In another preferred aspect, the present invention provides composition of oral film of Ivermectin and its pharmaceutically acceptable salt thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Ivermectin and its pharmaceutically acceptable salt; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In one preferred aspect, the present invention provides oral film of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts thereof.
In one preferred aspect, the present invention provides composition of oral film of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises at least one film forming polymer, plasticizer and one or more pharmaceutically acceptable excipients. In one aspect, the present invention provides process for preparing oral film of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the process may be selected from solvent casting, hot melt extrusion or printing technology.
In a preferred aspect, the present invention provides composition of oral film of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises from about 0.1% to about 75% by weight of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts thereof.
In another preferred aspect, the present invention provides composition of oral film of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts thereof, wherein the composition comprises: i. from about 0.1% to about 75% by weight of Ivermectin/Praziquantel combination and its pharmaceutically acceptable salts; ii. from about 1% to about 60% by weight of at least one film forming polymer; iii. from about 1% to about 30% by weight of plasticizer; and iv. one or more pharmaceutically acceptable excipients; wherein the percentage (%) by weight is relative to the total weight of the composition.
In one aspect, the present invention provides oral films of Anti-parasitic drugs and its pharmaceutically acceptable salts thereof used for the treatment or prevention of parasitic infections caused by Heartworms, Lungworms, Nodularworms, kidney worms; Intestinal worms like Tapeworms, Ringworms, Hookworms, Roundworms, whipworms; protozoans (non- worms) like Coccidia, Giardia, spirochetes; and external parasites like Flea, Mites, Ticks and Lice in animals.
The said invention is further illustrated by following non-limiting examples: which are set forth to aid in an understanding of the invention, and are not intended, and should not be construed, to limit in any way the invention set forth in the claims that follow thereafter. A person skilled in the art will readily recognize the various modifications and variations that may be performed without altering the scope of the present invention. Such modifications and variations are encompassed within the scope of the invention and the examples do not in any way limit the scope of the invention. Example 1:
Figure imgf000025_0001
Brief Manufacturing Procedure:
1. Dispense all the ingredients.
2. Add ethanol in a suitable stainless steel vessel and optionally add dichloromethane. 3. Add Hydroxypropyl methylcellulose to step 2 under stirring and continue stirring till a homogenous dispersion is obtained.
4. Optionally add Polyoxyl 40 hydrogenated castor oil or Polyoxyl 15 hydroxy stearate or Polysorbate 80 or poloxamer to step 3 under stirring and continue stirring till a homogenous dispersion is obtained. 5. Add Milbemycin oxime to the dispersion of step 3/4 under stirring and continue stirring till a homogenous dispersion is obtained.
6. Add Microcrystalline Cellulose to dispersion of step 5 under stirring and continue stirring till a homogenous dispersion is obtained.
7. Add Propylene glycol to dispersion of step 6 under stirring and continue stirring till a homogenous dispersion is obtained.
8. Add butylated hydroxyl toluene to step 7 under stirring and continue stirring till a homogenous dispersion is obtained.
9. Add colorant to dispersion of step 8 under stirring and continue stirring till a homogenous dispersion is obtained. 10. Add flavor to dispersion of step 9 under stirring and continue stirring till a homogenous dispersion is obtained.
11. Homogenize the dispersion of step 10 using a homogenizer to obtain a homogenous dispersion. 12. If any foam observed, de-aerate the dispersion by applying vacuum under slow stirring.
13. The dispersion of step 11/12 is casted using a film casting machine where the dispersion is spreaded on a backing film to form a thin wet film which passed through a drying zone.
14. The dried film is cut into a desired size by using slitter.
15. Pack the film into suitable pouches/sachets. Example 2:
Figure imgf000026_0001
Brief Manufacturing Procedure:
1. Dispense all the ingredients.
2. Add Ethanol in a suitable stainless steel vessel.
3. Add Hydroxypropyl cellulose and/or polyvinyl alcohol to step 2 under stirring and continue stirring till a homogenous dispersion is obtained.
4. Optionally add Polyoxyl 40 hydrogenated castor oil or Polyoxyl 15 hydroxy stearate or Polysorbate 80 or poloxamer to step 3 under stirring and continue stirring till a homogenous dispersion is obtained. 5. Add Afoxolaner to the dispersion of step 3/4 under stirring and continue stirring till a homogenous dispersion is obtained.
6. Add Starch to dispersion of step 5 under stirring and continue stirring till a homogenous dispersion is obtained.
7. Add Propylene glycol to dispersion of step 6 under stirring and continue stirring till a homogenous dispersion is obtained.
8. Add butylated hydroxyl toluene to step 7 under stirring and continue stirring till a homogenous dispersion is obtained.
9. Add colorant to dispersion of step 8 under stirring and continue stirring till a homogenous dispersion is obtained.
10. Add, flavor to dispersion of step 9 under stirring and continue stirring till a homogenous dispersion is obtained.
11. Homogenize the suspension of step 10 using a homogenizer to obtain a homogenous dispersion.
12. If any foam observed, de-aerate the dispersion by applying vacuum under slow stirring.
13. The dispersion of step 11/12 is casted using a film casting machine where the dispersion is spreaded on a backing film to form a thin wet film which passed through a drying zone.
14. The dried film is cut into a desired size by using slitter.
15. Pack the film into suitable pouches/sachets.
Example 3:
Figure imgf000027_0001
Manufacturing Procedure:
1. Required quantity of water was taken in a suitable stainless steel vessel and polymer Hypromellose E50 was added under stirring and continued stirring till a homogenous dispersion is obtained.
2. Added Propylene glycol to dispersion of step 1 under stirring and continued stirring till a homogenous dispersion is obtained.
3. Added Polysorbate 80 to dispersion of step 2 under stirring and continued stirring till a homogenous dispersion is obtained.
4. Added Crospovidone to step 3 under stirring and continued stirring till a homogenous dispersion is obtained.
5. Added flavor to dispersion of step 4 under stirring and continued stirring till a homogenous dispersion is obtained.
6. Ethanol was taken in a suitable stainless steel vessel. Added BHT and stirred with a suitable stirrer to till a clear solution was obtained.
7. Added Milbemycin oxime to the solution of step 6 and stirred with a suitable stirrer to get a homogenous dispersion.
8. The suspension of step 7 was added to the polymeric suspension of step 5 and homogenized using a homogenizer to obtain a homogenous suspension.
9. De-aerated the suspension by applying vacuum under slow stirring.
10. The dispersion is casted using a film casting machine where the dispersion is spreaded on a backing film to form a thin wet film which passed through a drying zone.
11. The dried film is cut into a desired size by using slitter.
12. Pack the film into suitable pouches/sachets
Disintegration study: The obtained oral film of Example 3 is tested for disintegration time using static method, wherein the oral film is placed in a petri dish containing water in a static condition and the time taken for disintegration is observed.
• Time taken for disintegration - 80 seconds
Therefore, oral films of the present invention formulated according to an embodiment has shown quick disintegration, which solves the problems mentioned above like difficulty of administration, swallowing, dosing errors etc in animals.

Claims

We claim:
1. An oral film of Anti-parasitic drug(s) and its pharmaceutically acceptable salt thereof for veterinary use.
2. The oral film as claimed in claim 1, wherein the Anti-parasitic drug(s) is selected from Milbemycin oxime, Ivermectin, Febantel, Albendazole, Thiabendazole, Fenbendazole, Mebendazole, Oxibendazole, Oxfendazole, Cambendazole, Arsenamide, Eprinomectin, Diethylcarbamazine, Coumaphos, Praziquantel, Levamisole, Pyrantel, Dichlorophene, Trichlorfon, Emodepside, Doramectin, Haloxon, Nitenpyram, N-butyl Chloride, Melarsomine, Phenothiazine, Butamisole, Thenium, Dichlorvos, Bacitracin methylene, Afoxolaner, Selamectin, Moxidectin, Imidacloprid, Spinosad, Lufenuron, Cythioate, Fenthion, Sarolaner, Fluralaner, Famphur, Phosmet, Lotilaner, Griseofulvin, Morantel, Bunamidine, Tolnaftate, Tioxidazole and combinations thereof and its pharmaceutically acceptable salt thereof.
3. The oral film as claimed in claim 1, wherein the film comprises: a. Anti-parasitic drug(s) and its pharmaceutically acceptable salt thereof selected from Milbemycin oxime, Ivermectin, Febantel, Albendazole, Thiabendazole, Fenbendazole, Mebendazole, Oxibendazole, Oxfendazole, Cambendazole, Arsenamide, Eprinomectin, Diethylcarbamazine, Coumaphos, Praziquantel, Levamisole, Pyrantel, Dichlorophene, Trichlorfon, Emodepside, Doramectin, Haloxon, Nitenpyram, N-butyl Chloride, Melarsomine, Phenothiazine, Butamisole, Thenium, Dichlorvos, Bacitracin methylene, Afoxolaner, Selamectin, Moxidectin, Imidacloprid, Spinosad, Lufenuron, Cythioate, Fenthion, Sarolaner, Fluralaner, Famphur, Phosmet, Lotilaner, Griseofulvin, Morantel, Bunamidine, Tolnaftate, Tioxidazole and combinations thereof; b. at least one film forming polymer; c. plasticizer; and d. one or more pharmaceutically acceptable excipients.
4. The oral film as claimed in claim 3, wherein the film forming polymer is selected from hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, sodium carboxy methylcellulose, methyl cellulose, Hydroxypropyl
28 ethylcellulose, povidone, copovidone, polydextrose, polyvinyl alcohol, polyvinyl acetate, polyethylene oxide, pullulan, sodium alginate, propylene glycol alginate, modified starch, gelatin, pectin, polyoxyethylene stearates, poly-epsilon caprolactone, polyglycolized glycerides, cyclodextrins, galactomannans, polymerized rosin, ethyl cellulose, Polymethacrylates, polyacrylic acid, methyl methacrylate copolymer, copolymers of acrylic acid and alkyl acrylate, carboxyvinyl copolymers and combinations thereof. The oral film as claimed in claim 3, wherein the plasticizer is selected from polyethylene glycol, propylene glycol, polyethylene -propylene glycol, glycerin, glycerol monoacetate, glycerol diacetate, glycerol triacetate, triacetin, polysorbate, cetyl alcohol, propylene glycol, sorbitol, sodium diethylsulfosuccinate, triethyl citrate, tributyl citrate, dimethyl phthalate, diethyl phthalate, dibutyl phthalate and combinations thereof. The oral film as claimed in claim 3, wherein one or more pharmaceutically acceptable excipients are selected from suspending/thickening agents, disintegrating agents, fillers/bulking agents, stabilizers, surfactants, sweetening agents, taste masking agents, buffering agents, anti-foaming agents, flavoring agents, and coloring agents. The oral film as claimed in claims 1 and 3, wherein the process of preparing oral film of Anti-parasitic drug(s) and its pharmaceutically acceptable salt thereof is by solvent casting, hot melt extrusion or printing technology thereof. The oral film as claimed in claims 1 and 3, wherein the oral film of Anti-parasitic drug(s) and its pharmaceutically acceptable salt thereof is administered to any nonhuman animal for the treatment or prevention of any parasitic infestation.
PCT/IN2022/051136 2021-12-30 2022-12-29 Oral films of anit-parasitic drugs WO2023126969A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202141062003 2021-12-30
IN202141062003 2021-12-30

Publications (1)

Publication Number Publication Date
WO2023126969A1 true WO2023126969A1 (en) 2023-07-06

Family

ID=86998441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2022/051136 WO2023126969A1 (en) 2021-12-30 2022-12-29 Oral films of anit-parasitic drugs

Country Status (1)

Country Link
WO (1) WO2023126969A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110251509A (en) * 2012-02-06 2019-09-20 勃林格殷格翰动物保健美国公司 Antiparasitic oral veterinary composition, method comprising the activating agent systemically to work and application thereof
WO2020077284A1 (en) * 2018-10-12 2020-04-16 Hovione Scientia Macrocyclic lactone formulations, methods of their preparation and use of the formulations in treating pathologies secondary to ophthalmic parasites

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110251509A (en) * 2012-02-06 2019-09-20 勃林格殷格翰动物保健美国公司 Antiparasitic oral veterinary composition, method comprising the activating agent systemically to work and application thereof
WO2020077284A1 (en) * 2018-10-12 2020-04-16 Hovione Scientia Macrocyclic lactone formulations, methods of their preparation and use of the formulations in treating pathologies secondary to ophthalmic parasites

Similar Documents

Publication Publication Date Title
DK1539116T3 (en) NON-ANIMAL PRODUCT CONTAINING VETERINARY FORMULATIONS
JP5681693B2 (en) Transmucosal administration of pharmaceutical compositions for treating and preventing disorders in animals
ES2210454T3 (en) FORMULATION CONTAINING VENLAFAXINE OF PROLONGED RELEASE.
US20130039932A1 (en) Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent
BR112014019262B1 (en) PARASITIC VETERINARY ORAL COMPOSITIONS INCLUDING SYSTEMIC ACTION ACTIVE INGREDIENTS, METHODS AND USE OF THE SAME
EP2519226A1 (en) Orally administrable film dosage forms containing ondansetron
JP2002179558A (en) Solid preparation
CN105193772A (en) Saxagliptin oral membrane and preparation method thereof
WO2021260641A1 (en) Oral film of hiv drugs
US20170100327A1 (en) Pharmaceutical composition with ionically crosslinked polymer encapsulation of active ingredient
CA3195133A1 (en) Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride
BR112019027286A2 (en) oral melatonin dissolution formulation with acidifying agent that makes melatonin soluble in saliva
TWI664969B (en) Compositions of grapiprant and methods for using the same
US20230381173A1 (en) Methods and pharmaceutical composition for treating diseases
TR201907905A1 (en) A COMBINATION WITH ALOGLIPTIN AND METFORMIN
US20090269393A1 (en) Chewable Bilayer Tablet Formulation
WO2023126969A1 (en) Oral films of anit-parasitic drugs
WO2023126971A1 (en) Oral films of anti-emetic drugs
JP2012031164A (en) Film-shaped preparation
WO2023126967A1 (en) Oral films of antipruritic drugs
WO2023126970A1 (en) Oral films of non-steroidal anti-inflammatory drugs
US20230381109A1 (en) Orally disintegrating tablet comprising benzimidazole derivative compound and preparation method thereof
US20220211689A1 (en) Orally disintegrating pharmaceutical compositions of apixaban
US11446243B1 (en) Oral liquid compositions including valsartan
WO2022190126A1 (en) Oral film of cftr modulator(s)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22915391

Country of ref document: EP

Kind code of ref document: A1